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HIV vaccine candidates with improved immunogenicity and induction of mucosal T-cell immunity are needed. A prime-boost
strategyusinganovelHIVglycoprotein120DNAvaccinewasemployedtoimmunizerhesusmacaques.TheDNAvaccineencoded
a chimeric gp120 protein in fusion with monocyte chemoattractant protein-3, which was hypothesized to improve the ability of
antigen-presenting cells to capture viral antigen through chemokine receptor-mediated endocytosis. DNA vaccination induced
virus-reactiveTcellsinperipheralblood,detectablebyTcellproliferation,INFγ ELISPOTandsustainedIL-6production,without
humoral responses. With a peptide-cocktail vaccine containing a set of conserved polypeptides of HIV-1 envelope protein, given
by nasogastric administration, primed T-cell immunity was signiﬁcantly boosted. Surprisingly, long-term and peptide-speciﬁc
mucosalmemoryT-cellimmunitywasdetectedinbothvaccinatedmacaquesafteroneyear.Therefore,datafromthisinvestigation
oﬀer proof-of-principle for potential eﬀectiveness of the prime-boost strategy with a chemokine-fused gp120 DNA and warrant
further testing in the nonhuman primate models for developing as a potential HIV vaccine candidate in humans.
1.Introduction
Acquired immunodeﬁciency syndrome (AIDS) is a life-
threatening viral disease caused by a severely impaired
immune defense mechanism resulting from devastation of
CD4+ T lymphocytes by human immunodeﬁciency virus-
1 (HIV-1). A fundamental concept in controlling AIDS
development is to prevent the loss of CD4+ T cells, which
may be achieved by inhibiting intracellular viral replication
and eliminating virus-infected cells. A therapeutic HIV
vaccine that aims at activating adaptive T-cell immunity to
prevent intercellular spread of viruses is therefore required to
curb the rapid worldwide spread of this disease. Although
enormous eﬀorts have been made to test a variety of
vaccine strategies, the generation of an HIV vaccine with
potent antiviral eﬀects remains elusive. One major obstacle
hampering vaccine development is the low magnitude of
vaccine-elicited immunity. To overcome this issue, current
attention is mainly focused on developing strategies to
enhance the immunogenicity of HIV vaccine formulations
andtheinductionofmucosalimmunity.Theseattemptshave
included the delivery of HIV antigen genes by live recombi-
nant adenovirus or mycobacterium, resulting in an improved
HIV-speciﬁc immune response [1, 2]. The critical role of
dendritic cells in initiating the adaptive immune response is
well recognized by their function in capturing, processing,
and presenting antigens. Other strategies that speciﬁcally
target delivery of antigens to dendritic cells may therefore
increase the potency of antigen-speciﬁc immune responses
[3–5]. Chemokines are a family of chemotactic polypeptides2 Journal of Biomedicine and Biotechnology
that facilitate the homing of antigen-bearing dendritic cells
to draining lymph nodes. Chemokine-induced signal trans-
duction is triggered by the binding of chemokines with G-
protein—coupled receptors and is subsequently terminated
by the clathrin-mediated endocytosis of the chemokine-
receptor complex. Given these features of chemokine recep-
tors on dendritic cells, we previously described achievement
of triggering potent T-cell responses by fusion of candidate,
otherwise non-immunogenic antigens with chemokines,
hypothesizing that the chemokine motif in the chimeric
proteins would direct antigens to dendritic cells or other
antigen-presenting cells in the body. Speciﬁcally, using HIV-
1 89.6 envelope glycoprotein 120 as a model antigen, we
veriﬁed that genetic fusion of this candidate HIV antigen
with chemokines dramatically increased its immunogenicity
in mice [6]. Both systemic and mucosal HIV-speciﬁc T-
cell immunities were elicited upon immunizing mice with
plasmidDNAencodingthefull-lengthgp120genefusedwith
monocyte chemotactic protein-3 (MCP3). In the present
proof-of-principle pilot study, we show for the ﬁrst time that
an MCP3-fused gp120 DNA vaccine elicited virus-speciﬁc T-
cell immunity in rhesus macaques at a dose of only 20μgo f
plasmid DNA. The elicited T-cell response was boosted by
nasal administration of a peptide-cocktail consisting of six
highly conserved epitopes of the HIV-1 envelope protein. A
highly desirable feature of this prime-boost strategy was the
induction of long-term mucosal T-cell immunity.
2.MaterialsandMethods
2.1. Vaccination of Animals. The macaque study was per-
formed under a protocol approved by the Institutional
Animal Care and Use Committee of The University of
Texas, M. D. Anderson Cancer Center. Two male rhesus
macaques of Indian origin (designated J8 and J160) from
the institution’s speciﬁc pathogen-free breeding colony at
the Science Park campus in Bastrop, Texas were used for
the study. The animal facility is fully accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care International. The plasmid DNA encoding
MCP3-fused gp120 was generated as described in our
previous studies [6]. The DNA was precipitated in the
presence of 1μm gold particles (BioRad, Hercules, CA) and
the polycation spermide by the addition of calcium chloride.
TheDNA-attachedgoldparticleswerewashedandresuspend
in ethanol, coated onto the inner wall of Gold-Coat tubing
(BioRad), dried and cut into 0.5” length cartridge. These
cartridges were inserted into the cartridge holder of the
Helio Gene Gun (BioRad). By helium discharge the DNA
was directly delivered into skin. The particle-coated plasmid
DNA was delivered intradermally using helium gene gun
(BioRad) at 400psi. A total amount of approximate 20μg
DNA was evenly distributed at shaved areas on each arm or
leg. The booster dose of the peptide-cocktail vaccine consists
of six highly conserved HIV-1 envelope peptides (each at
100μg/dose/macaque). The peptide synthesis, amino acid
sequence, and immunogenicity were reported previously
[7–9]. The peptide-cocktail was administered by naso-
gastric route along with a mutant cholera toxin, CT2∗
(10μg/dose/monkey) that we reported previously to be a
safe and eﬀective mucosal adjuvant in murine and primate
models [10, 11] in 600μL sterile PBS.
2.2. Collection of Samples. Peripheral venous blood samples
collected in sodium heparin at diﬀerent time points were
centrifuged to separate plasma and buﬀyc o a t .P e r i p h e r a l
blood mononuclear cells (PBMC) were separated from
buﬀy coat by centrifugation through Ficoll-Paque density
gradients and were used for various immune assays. Also,
serum samples were collected and stored at −80
◦Cf o r
analysis of the neutralizing antibody. The intraepithelial
lymphocytes (IEL) from the colon biopsy sections of the
macaques were isolated by using modiﬁcations of previously
described procedures [12]. Brieﬂy, 10–15 samples of colon
biopsy (2mm each) were collected and rinsed in cold PBS.
The tissue was treated with dithiothreitol (DTT, 1.5mg/mL)
in Hank’s balanced salt solution (HBSS) for 30 minute at
RT with agitation to remove mucus. The tissue were then
treated with 0.75mM EDTA in Ca2+-a n dM g 2+-free HBSS
at RT for 60 minute with stirring. After the treatment, the
supernatants containing epithelial cells were removed and
digestedwith15UofcollagenaseDandDNAseIincomplete
RPMI 1640 medium containing 100U of penicillin and
100Uofstreptomycinperml,5mlL-glutamine,5mlHEPES
buﬀer, and 10% FCS at 37
◦C with rapid shaking for 2 hours.
The resulting cell suspensions were passed through stainless
steel screen cups to remove the residual tissue fragments.
The cells were washed and resuspended in complete RPMI
1640 medium and enriched for lymphocytes by isotonic
discontinuousPercoll(Sigma)densitygradients(35and60%
[vol/vol]) at 1,000g for 20 minute at 4◦C. The lymphocyte
band at the interface between the 35 and 60% Percoll
layers was collected. Viability of lymphocytes was greater
than 95% as determined by the Trypan blue dye exclusion
method. Aliquots of freshly-isolated cells were stained with
ﬂuorescently-labeled antibodies for ﬂow cytometry analysis.
2.3.ProliferationAssay. Proliferativeresponses ofPBMCiso-
lated from immunized macaques were determined using the
standard [3H] thymidine incorporation assay as described
earlier [13]. Brieﬂy, 100μL aliquots of the cell suspensions
(1 × 105 cells in complete RPMI) were dispersed into
triplicate wells of a round-bottom 96-well microtiter plate
and incubated with the HIV-1 envelope peptides (10μg/mL
ﬁnal concentration) as a single mixture (designated as pep-
mix) and the cell-free heat-inactivated SHIV89.6P (equivalent
to 50ng/ml ﬁnal concentration of p27) prepared by incu-
bating for 60 minute at 56
◦C. The proliferative response
was calculated as the fold increase in radioactivity with
the test antigen over that for cells cultured in the medium
alone and is represented as the stimulation index (SI). The
responses to peptides were considered positive when the SI
values are 2.0 or greater, and also 2.0 above the value for
the negative control peptide (from human papilloma virus
at 10mg/mL ﬁnal concentration) or medium control used in
the same experiment. No diﬀerences were observed between
the negative control peptide and culture medium as control
treatments.Journal of Biomedicine and Biotechnology 3
2.4. Measurement of IFN-γ Production by ELISPOT Assay.
PBMC isolated from immunized macaques were stimulated
with the mixture of the HIV-1 envelope peptides and
cell-free, heat-inactivated SHIV89.6P for determining the
antigen-speciﬁc interferon-γ (IFN-γ)-producing cells by the
ELISPOT analyses, as reported earlier [13]. The membranes
werereadbyanindependentagency(ZellnetConsultingInc.,
New York, NY, USA) using the KS-ELISPOT automatic sys-
tem (Carl Zeiss, Inc., Thornwood, NY, USA) for quantitative
analyses of the number of IFN-γ spot forming cells (SFC)
for 105 input PBMC. Responses were considered positive,
according to criteria described in the literature [13], which
is a minimum of ﬁve SFC per well and at least double the
number obtained in cells cultured in the medium.
2.5. Cytokine Analysis by Cytokine Bead Array (CBA). Single
cell suspensions of PBMC from the immunized monkeys
were cultured at a density of 1 × 105 p e rm Lw i t ho rw i t h o u t
the HIV-1 envelope peptide mixture and cell-free heat-
inactivated SHIV89.6P to detect antigen-speciﬁc cytokine
production. Culture supernatants were collected 36 h after
incubation,andthelevelofcytokines(IL-2,IL-4,IL-6,IL-10,
IL-12p70, IFN-γ,a n dT N F - α) was determined by cytometric
beadarray(CBA)kit(Lincoplexmultiplecytokineassay,Mil-
lipore), according to manufacturer’s instructions. Antigen-
speciﬁc cytokine production was measured as the cytokine
concentration in culture supernatants of antigen-stimulated
cells subtracting that without antigen.
2.6. Intracellular Cytokine Analyses. The PBMC along with
lamina propria lymphocytes (LPL) isolated from the colon
biopsies as previously described [13], were used for the
analysesofantigen-speciﬁcintracellularcytokineproduction
using the following antihuman monoclonal antibodies that
cross-react with rhesus macaques: CD3 (clone SP34-2, PE-
Cy7-labeled), CD8a (clone RPA-T8, Alexa 700-labeled),
CD28(cloneL293,PerCP-Cy5.5-labeled),CD95(cloneDX2,
APC-labeled), and IFN-γ (clone B27, FITC-labeled; all from
BD Biosciences, San Jose, Calif, USA), CD4 (clone OKT4,
Paciﬁc blue-labeled; eBioScience, San Diego, Calif, USA),
and Aqua (live/dead staining kit) from Invitrogen (Carlsbad,
Calif, USA) to detect dead cells. The CD4+ and CD8+ Tc e l l s
that produce IFN-γ in response to stimulation with various
reagents were analyzed by the standard intracellular cytokine
assay procedure, as previously described [14]. Samples were
collected on a three-laser CYAN ADP instrument (Dako
Cytomation, Glostrup, Denmark) and analyzed using FloJo
software (Tree Star, Ashland, OR). For data acquiring and
analyzing, CD3+CD8+ or CD3+CD4+ T cells initially gated
from live lymphocytes were further gated for CD95 memory
phenotype. The gated CD4+ or CD8+ memory T cells were
then analyzed for positive staining of IFNγ.
3. Results andDiscussion
We used nonhuman primates to evaluate the translational
potential for the chemokine-fusion strategy in the develop-
ment of a novel HIV vaccine. Two macaques immunized
with the plasmid DNA encoding MCP3-gp120 fusions
demonstrated virus-reactive T-cell immunity at week 12,
evidenced by the proliferation of T cells (Figure 1(a))a n d
IFN-γ producing cells in response to in vitro stimula-
tion with heat-inactivated SHIV89.6P (Figure 1(b)). Peptide-
cocktail vaccine boosted the viral-reactive T-cell immunity,
as evidenced by the signiﬁcant elevation of IFN-γ producing
cells in response to the heat-inactivated SHIV89.6P in one
of the two monkeys (Figure 1(b) #J160). The peptide-
cocktail-speciﬁc response was readily detected after peptide
boost, conﬁrming the immunogenicity of the peptide-
cocktail vaccine (Figure 1(c)). The macaque (#J8) that was
weakly responsive to the peptide boost (Figure 1(b) #J8)
also showed a low magnitude of peptide-cocktail-speciﬁc
systemic cellular responses (Figure 1(c)). PBMC cultured
with medium or treated with irrelevant human papilloma
virus peptide failed to show positive responses (data not
shown). We were unable to detect antibody responses, either
by neutralization assay or by Western blot (data not shown).
To further investigate changes in the DNA vaccine-
induced microenvironment that may facilitate the develop-
ment of memory immunity, we monitored virus-reactive,
PBMC cytokine induction throughout the entire prime-
boost schedule. Strikingly, among a panel of cytokines
including IL-2, IL-4, IL-6, IL-10, IL-12p70, IFN-γ,a n d
TNF-α, production of IL-6 was found to be signiﬁcantly
increased upon initial vaccination with MCP-3-fused gp120
plasmid DNA. Of interest, immune cells harvested from
the monkey #J160 during the boost period (W32–39) were
considerably more active in producing IL-6, compared with
PBMC collected from the macaque #J8 (Figure 1(d)).
We analyzed colon biopsy samples collected from
the macaques one year after the ﬁnal peptide-cocktail
boost. During this year-long rest period the two vacci-
nated macaques received no further treatment. Surprisingly,
antigen-speciﬁc CD4 and CD8 memory T cells were detected
in lamina propria lymphocytes (LPL) isolated from the
colon, suggesting long-term mucosal immunity. Speciﬁcally,
after in vitro stimulation with the peptide-mix, subsets of
IFN-γ-producingCD3+CD4+CD95+ andCD3+CD8+CD95+
T cells were readily detected in both vaccinated macaques
(Figure 2) .T h em e m o r yTc e l lr e s p o n s ew a sf o u n do n l yi n
LPL samples, but not in PBMC (Figure 2). These results
suggest that the immunization regimen induced mucosal
memory cellular immune responses, which likely resulted
from directly delivering viral antigen to the gastrointesti-
nal mucosa by nasogastric administration of the peptide-
cocktail.
Growing evidence has emphasized the central role of
cellular immunity in the control of HIV infection. For
example, the prevalence of virus-speciﬁc cytotoxic T cells
has been associated with reduced viral RNA load and
delayedclinicalprogressionofthedisease[15].Innonhuman
primate models, depletion of CD8+ Tl y m p h o c y t e sr e s u l t e d
in marked viral replication in chronically infected animals
[16]. It is thus important to focus development of HIV
vaccines that generate cellular immunity for therapeutic
beneﬁt. In this pilot study, we observed that the MCP3-
fused gp120 DNA vaccine elicited the viral-reactive T-cell
immunity in rhesus macaques that were vaccinated with4 Journal of Biomedicine and Biotechnology
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Figure 1:ImmunizationofrhesusmacaqueswithplasmidDNAencodingMCP3-gp120fusionprimedviral-reactiveT-cellimmunity,which
was further boosted by HIV-1 envelope peptide-cocktail vaccine. The DNA priming schedule included four rounds of immunization at 1-
month intervals. Two rhesus macaques were immunized with 20μg of the plasmid DNA by gene gun injection at weeks 0, 4, 8, and 12. The
boosting schedule included a peptide-cocktail vaccine that contains six highly conserved peptides from the HIV-1 envelope protein. After a
rest period of 20 weeks following the ﬁnal round of DNA vaccination to allow for the establishment of memory T cells, the peptide-cocktail
boosts were administered by intranasal route along with a mutant cholera toxin on Weeks 32 and 37. Peripheral blood mononuclear cells
collected after DNA vaccination revealed viral-reactive T-cell immunity as evidenced by the cell proliferation (a) and IFN-γ producing cells
(b)inresponsetoinvitrostimulationwithcell-free,heat-inactivatedSHIV89.6P antigen-speciﬁcT-cellimmunitywasboostedbythepeptide-
cocktail vaccine, especially in #J160 showing signiﬁcant elevation of IFN-γ producing cells in response to heat-inactivated SHIV89.6P)( b ) .
The immunogenicity of the peptide vaccine was conﬁrmed by analysis of peptide-speciﬁc T-cell immunity (c). Vaccine-induced cytokine
production was examined using LINCOplex multiple cytokine luminescent assay. Among the cytokines assayed, IL-6 was predominantly
detectedinbothmacaquesafterDNAvaccinationatWeek12.Virus-reactiveIL-6secretionwasmoreapparentinmonkey#J160,particularly
during the period of peptide-cocktail boost.Journal of Biomedicine and Biotechnology 5
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Figure 2: The immunization strategy elicited mucosal long term memory T-cell immune responses. Production of IFN-γ by CD3+CD4+
or CD3+CD8+memory T cells isolated from colon was analyzed in the vaccinated macaques one year after ﬁnal peptide-cocktail boost.
Lamina propria lymphocytes (LPL) from colon biopsy samples were stimulated with peptide-mix or mitogens for 6 h. Both untreated
(control) and stimulated cells were stained for surface markers, followed by ﬁxation, permeabilization, and intracellular staining of IFN-γ.
Live cells were identiﬁed by gating on Aqua-negative cells. The cells gated on CD3+CD4+ and CD3+CD8+ were further separated as memory
population according to the expression of CD95 (data not shown). The percentage values indicate the population of IFN-γ—producing
CD3+CD95+CD4+ or CD3+CD95+CD8+ lymphocytes.
as little as 20μg of plasmid DNA by gene gun injection.
Although the individual response in terms of immunity
potency was not robust, the immunogenicity of MCP3-
gp120 fusions DNA vaccine in a nonhuman primate model
was supported from the data obtained. Thus, future studies
are warranted to conﬁrm and extend the data from the
proof-of-principle study employing bigger cohort of animals
combined with determining protective eﬃcacy against viral
challenge. Furthermore, optimizing DNA delivery may
also help to enhance the immunogenicity of the vaccine
strategy. For example, we currently developed an immune
potentiating strategy by inducing a sterile inﬂammation
at vaccination sites, which signiﬁcantly potentiated DNA
vaccine-induced adaptive immunity [17]. Nevertheless, the6 Journal of Biomedicine and Biotechnology
take-home message that MCP3-gp120 DNA vaccine induced
T-cell immunity in macaques provides us with a rationale to
further optimize the chemokine-fusion strategy for design-
ing the next generation of HIV vaccines.
In contrast to activation of T-cell immunity, the fusion
vaccine failed to induce antibody response. This may imply
that antigen cross-presentation mechanism was predom-
inantly responsible for the observed adaptive immunity.
A striking feature of the chemokine fusion strategy is
its receptor-mediated endocytosis that facilitates loading
antigens to the MHC Class I pathway and thus polarizes Th1
response [18]. Accordingly, we also observed in mice that
chemokine-chicken ovalbumin fusion vaccine stimulated
expansion of adoptively transferred antigen-speciﬁc CD8+
(OT-I), but not CD4+ (OT-II) T cells (unpublished data).
Mucosal entry is a major route of HIV infection. A recent
clinical study suggests that blocking mucosal viral transmis-
sion would be critical to the prevention of systemic spread of
HIV [19]. The local mucosal immunity brings an additional
beneﬁcial inﬂuence to disease control. Therefore, an ideal
HIV vaccine should be designed to activate both systemic
and local immune responses. Our current study showed that
nasogastric administration of multivalent antigen peptides
not only boosted the genetic fusion-primed T cell immunity,
but also elicited mucosal immunity. The antigen-speciﬁc,
long-lasting T cell immunity was readily detected a year
later after ﬁnal vaccination, which renders our prime-boost
strategy with an extra advantage in the aspect of prophylactic
value.
Cytokines produced in the microenvironment may
be mechanistically associated with the elicited immune
response. Of particular interest in the current study was
the signiﬁcant increase in IL-6 upon vaccination with
chemokine-fused gp120 plasmid DNA. This T-cell—derived
cytokine was initially identiﬁed as a B-cell growth and
diﬀerentiation factor [20] and was subsequently discovered
to have a variety of biological activities, such as stimulating
diﬀerentiation of myeloid precursors, activating T cells by
enhancing IL-2 responsiveness, and regulating acute phase
reaction[21–23].ThestimulatoryfunctionofIL-6ondiverse
immune cells renders this cytokine a potential immune
adjuvant in the development of adaptive immune response.
The current study does not allow us to diﬀerentiate the
mechanism that caused the production of IL-6. Since IL-
6 is not constitutively produced by T cells, rather it is the
c o n s e q u e n c eo ft i s s u ed a m a g ea ss e e ni nt h ec a s eo fv i r a lo r
bacterial infection, we speculate that the viral gp120 protein
componentinthefusionconstructoftheDNAvaccinemight
be the stimulator for IL-6 production. Regardless of the
underlining mechanism, our observation that sustained IL-
6 production was correlated with vaccine boosting suggests
a potential role of this cytokine in the maintenance of long-
term memory immunity.
Future studies exploring the use of the chemokine-fusion
strategy to develop vaccines targeting other HIV antigens
including pol and gag gene products may be worthwhile. It
has been reported that multivalent vaccines demonstrated
superior antiviral eﬀect over single antigen-derived vaccines
[24]. Combined with more eﬃcient vaccinia viral vectors
[24], we expect that DNA vaccines encoding multivalent
HIV antigens fused with chemokines would be promising
candidates for HIV vaccines.
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